PRACTICAL GUIDE | 2026

El Salvador, Panama, Chile, Costa Rica: Inside Latin America's Fast-Track FIH Corridor

Speed is a pathway design, not a shortcut.

By Julio G. Martinez-Clark

CEO, bioaccess®

Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.

Publishing package

FIH is first-in-human: the first time a device or drug is tested in people. Sponsors ask which Latin American country activates fastest, and the honest answer has been stable for years: Panama, El Salvador, Chile, and Costa Rica. This is the fast-track FIH corridor — not because standards are lower, but because the pathway is designed for speed: ethics committee and regulator receive submissions in parallel rather than sequentially, committee cadence is frequent, and requirements are predictable.

A companion post — How Long Does It Take to Start a First-in-Human Trial in Latin America? A Country-by-Country Startup Clock — publishes the comparison table across all major markets. This post is the deep dive: why each corridor country is fast, what infrastructure each offers, where each falls short, and which study types fit. Timelines below are drawn from bioaccess® operational experience; treat country-level clocks as indicative and confirm the current pathway before planning around them.

Why is Panama the corridor's proven sprinter?

Panama is the country bioaccess® cites when sponsors ask whether fast activation is real: 'We got it activated in about 15 days in Panama.' The mechanics behind that number: the ethics submission receives an ID number in about three business days, the Ministry of Health (MINSA) pathway runs in parallel with the ethics review, and requirements are few — 'we barely get any requirements.'

• Speed drivers: parallel ethics/regulator submissions; ~3-business-day ethics ID; predictable, light requirements.
• Infrastructure: experienced private-hospital research sites; established trial import mechanics.
• Where it falls short: small population — recruitment can be the constraint, not the approval. Panama rewards narrow, well-defined indications and punishes optimistic enrollment models.
• Cost tier: mid-to-upper among corridor countries; hospital fees run higher than El Salvador's.
• Best fit: small early cohorts where speed to first-patient-in dominates and the indication matches available patient flow.

What makes El Salvador the cost leader?

El Salvador matches the corridor on pathway speed and undercuts it on cost. Julio's standing comparison: 'hospital fees in El Salvador are way less than in Panama.' For budget-sensitive FIH programs, that gap can decide the country.

• Speed drivers: fast ethics and regulatory pathway; parallel submissions where applicable.
• Infrastructure: capable hospital sites at a lower cost tier; growing investigator experience with early-stage trials.
• Where it falls short: small population and a thinner investigator bench than Panama or Chile — backup sites matter more here.
• Cost tier: the corridor's cost leader on hospital and site fees.
• Best fit: cost-sensitive FIH programs with modest enrollment targets and a defined patient population.

Why does Chile punch above its weight?

Chile is the corridor country that also sits in the top tier of perceived data rigor — alongside Brazil, Argentina, Mexico, and Colombia in how regulators and partners view its clinical data. That combination is rare: corridor speed without the 'small fast market' discount some sponsors worry about.

• Speed drivers: efficient ethics and Instituto de Salud Pública (ISP) pathways; experienced committees.
• Infrastructure: deep investigator bench, strong academic hospitals, mature research ecosystem.
• Where it falls short: higher cost tier than El Salvador or Panama; competition for top investigators and sites.
• Cost tier: upper among corridor countries — you pay for depth and perception.
• Best fit: programs where the FIH data must impress FDA reviewers or licensing partners, and where enrollment needs a real investigator bench.

What does Costa Rica offer?

Costa Rica completes the corridor: a fast, stable pathway with solid hospital infrastructure and a research-friendly regulatory posture. It is the corridor's quiet option — less cited in sponsor conversations than Panama, but consistent in execution.

• Speed drivers: streamlined ethics and Ministry of Health pathway; predictable requirements.
• Infrastructure: strong private-hospital sector; experienced coordinators.
• Where it falls short: small population like the rest of the corridor; investigator depth concentrated in a few centers.
• Cost tier: mid-range within the corridor.
• Best fit: sponsors who want corridor speed with institutional stability and are comfortable with concentrated site options.

How do the four corridor countries compare?

Country	Speed driver	Key strength	Key limitation	Cost tier
Panama	Parallel submissions; ~3-business-day ethics ID; ~15-day activation achieved	Proven speed record	Small population; enrollment risk	Mid-upper
El Salvador	Fast ethics/regulatory pathway	Lowest hospital/site fees in the corridor	Thinnest investigator bench	Lowest
Chile (ISP)	Efficient ethics + ISP pathway	Top-tier perceived data rigor + investigator depth	Higher cost; site competition	Upper
Costa Rica	Streamlined ethics/Ministry pathway	Stable institutions; solid private hospitals	Concentrated sites; small population	Mid

Clocks are indicative and drawn from bioaccess® operational experience — confirm the current pathway per country before building a program around any specific number.

Which study types fit the fast-track FIH corridor — and which do not?

• Strong fit: small first-in-human cohorts (the classic 5–15 patient early study); early feasibility studies; programs where months of runway are worth more than marginal per-patient savings.
• Conditional fit: moderate-enrollment studies, if feasibility confirms real patient flow at the specific sites — investigator interest beats headline population.
• Poor fit: large-enrollment programs that need deep patient pools; indications with no established referral flow in small markets. That is when the major markets (Brazil, Mexico, Colombia, Argentina) earn their longer clocks.

The recurring mistake: picking the fastest country, then discovering the indication cannot enroll there. Speed to activation means nothing if enrollment never starts. Inside Latin America's fast-track FIH corridor, feasibility — real site-level patient flow for your indication — is the selection step that matters more than the startup clock.

Frequently asked questions

Which Latin American country is fastest for a first-in-human trial?

Panama, El Salvador, Chile, and Costa Rica form the fast-track FIH corridor, with activation measured in weeks versus 6–9 months in the major markets. Panama holds the demonstrated record at bioaccess: about 15 days to activation.

Why is Panama so fast for clinical trial startup?

Ethics committee and regulator (MINSA) submissions run in parallel; the ethics submission receives an ID in about three business days; and requirements are light — 'we barely get any requirements.' It is pathway design, not lower standards.

Is El Salvador really cheaper than Panama for FIH trials?

On hospital and site fees, yes — materially so, in bioaccess® experience. El Salvador is the corridor's cost leader, which makes it the value option for budget-sensitive programs with modest enrollment needs.

Does fast mean lower data quality for FDA purposes?

No. FDA acceptance turns on ICH-GCP (International Council for Harmonisation Good Clinical Practice) compliance and qualified sites and investigators, not on how fast the trial activated. Chile additionally offers top-tier perceived data rigor for sponsors who need it.

What is the biggest risk of choosing a fast-corridor country?

Enrollment. All four are small markets; the approval is rarely the constraint — patient flow is. Model enrollment from actual site flow, not population, and prequalify backup sites.

Should we run feasibility in more than one corridor country?

Yes. Test two to three countries and let the feasibility numbers choose. That screening costs little and is the cheapest insurance in the program.

Find your corridor fit before you commit to a clock

Inside Latin America's fast-track FIH corridor, the right country is the one whose patient flow matches your indication — not simply the fastest one. bioaccess® runs feasibility across two to three corridor markets, models enrollment from real site flow, and activates in weeks where the data supports it.

Talk with bioaccess® about your Latin America FIH strategy

Regulatory references

• Panama: Ministry of Health (MINSA) clinical trial and ethics submission procedures; timelines per bioaccess® operational experience, confirm current procedure at filing.
• El Salvador: national clinical trial authorization procedures; cost comparisons per bioaccess® operational experience.
• Chile: Instituto de Salud Pública (ISP) clinical trial procedures; confirm current procedure at filing.
• Costa Rica: Ministry of Health clinical trial procedures; confirm current procedure at filing.
• ICH E6 Good Clinical Practice (GCP).
• bioaccess® blog: How Long Does It Take to Start a First-in-Human Trial in Latin America? A Country-by-Country Startup Clock (2026).
• bioaccess® blog: Will the FDA Accept Data from a Latin American First-in-Human Trial? (2026).